Tegileridine versus Sufentanil for Patient-Controlled Intravenous Analgesia After Cesarean Delivery: A Randomized Double-Blind Trial.
Jing Hu, Lianchun Ou, Fangyun Wei et al.
✦ AI-curated · Sources linked
From the abstract
Postoperative nausea and vomiting (PONV) remains one of the most common opioid-related adverse events after cesarean delivery despite multimodal analgesia. Tegileridine, a biased μ-opioid receptor agonist, may offer effective analgesia with fewer opioid-related adverse events.
Reported results
Ninety-two participants completed the study. Compared with the sufentanil group, the tegileridine group had a lower incidence of PONV (6.5% vs 23.9%; RR = 0.27 (95% CI: 0.08-0.91); OR = 0.22 (95% CI: 0.06-0.86); ARD = -17.4% (95% CI: -31.6 to -3.1%); P=0.039) and dizziness (6.5% vs 26.1%; P=0.022).
Authors' conclusions
Among women undergoing cesarean delivery, tegileridine-based PCIA was associated with a lower incidence of PONV and dizziness and improved postoperative recovery quality compared with sufentanil, while postoperative analgesic outcomes were not significantly different between groups. These findings warrant confirmation in larger multicenter studies before routine clinical adoption.